Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans

Journal of Clinical Investigation

Volumn 111, Issue 8, 2003, Pages 1241-1250

  McDermott, David H ^a   Fong, Alan M ^b   Yang, Qiong ^c   Sechler, Joan M ^a   Cupples, L Adrienne ^c   Merrell, Maya N ^a   Wilson, Peter W F ^d   D'Agostino, Ralph B ^e   O'Donnell, Christopher J ^f,g   Patel, Dhavalkumar D ^b   Murphy, Philip M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Boston University   (United States)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^g FRAMINGHAM HEART STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR1 M280; CX3C CHEMOKINE; FRACTALKINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL PROTECTION; CELL TYPE; CHEMOTAXIS; ENDOTHELIUM CELL; GENE MUTATION; GENETIC RISK; LEUKOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FAMILY; SHEAR STRESS; SMOOTH MUSCLE FIBER;

EID: 0242515752     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI16790     Document Type: Article

References (52)

1. Desai, M.M., Zhang, P., and Hennessy, C.H. 1999. Surveillance for morbidity and mortality among older adults-United States, 1995-1996. MMWR CDC Surveill. Summ. 48:7-25.2.
2. Wilson, P.W. 1999. Metabolic risk factors for coronary heart disease: current and future prospects. Curr. Opin. Cardiol. 14:176-185.
3. Myers, R.H., Kiely, D.K., Cupples, L.A., and Kannel, W.B. 1990. Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am. Heart J. 120:963-969.
4. Ross, R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340:115-126.
5. O'Donnell, C.J., and Levy, D. 2000. Weighing the evidence for infection as a risk factor for coronary heart disease. Curr. Cardiol. Rep. 2:280-287.
6. Libby, P., Ridker, P.M., and Maseri, A. 2002. Inflammation and atherosclerosis. Circulation. 105:1135-1143.
7. McDermott, D.H. 2000. Chemokines and their receptors in infectious disease. Springer Semin. Immunopathol. 22:393-415.
8. Murphy, P.M., et al. 2000. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52:145-176.
9. Reape, T.J., and Groot, P.H. 1999. Chemokines and atherosclerosis. Atherosclerosis. 147:213-225.
10. Abi-Younes, S., et al. 2000. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ. Res. 86:131-138.
11. Greaves, D.R., et al. 2001. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler. Thromb. Vase. Biol. 21:923-929.
12. Wong, B.W., Wong, D., and McManus, B.M. 2002. Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc. Pathol. 11:332-338.
13. Boring, L., Gosling, J., Cleary, M., and Charo, I.F. 1998. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 394:894-897.
14. Gu, L., et al. 1998. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprocein receptor-deficient mice. Mol. Cell. 2:275-281.
15. Dawson, T.C., Kuziel, W.A., Osahar, T.A., and Maeda, N. 1999. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 143:205-211.
16. Fong, A.M., et al. 1998. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J. Exp. Med. 188:1413-1419.
17. Harrison, J.K., et al 1999. Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart. J. Leukoc. Biol. 66:937-944.
18. McDermott, D.H., et al. 2001. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ. Res. 89:401-407.
19. Moatti, D., et al. 2001. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood. 97:1925-1928.
20. Bazan, J.F., et al. 1997. A new class of membrane-bound chemokine with a CX3C morif. Nature. 385:640-644.
21. Pan, Y., et al. 1997. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation [erratum 1997, 389:100]. Nature. 387:611-617.
22. Imai, T., et al. 1997. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 91:521-530.
23. Haskell, C.A., Cleary, M.D., and Charo, I.F. 1999. Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J. Biol. Chem. 274:10053-10058.
24. Yoneda, O., et al. 2000. Fractalkine-mediated endothelial cell injury by NK cells. J. Immunol. 164:4055-4062.
25. Garton, K.J., et al. 2001. Tumor necrosis factor-alpha-converting enzyme (ADAM 17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem. 276:37993-38001.
26. Tsou, C.L., Haskell, C.A., and Charo, I.F. 2001. Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J. Biol. Chem. 276:44622-44626.
27. Goda, S., et al. 2000. CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J. Immunol. 164:4313-4320.
28. Murphy, P.M. 1994. The molecular biology of leukocyte chemoattractant receptors. Annu. Rev. Immunol. 12:593-633.
29. Harrison, J.K., et al. 2001. Mutational analysis of the fractalkine chemokine domain. Basic amino acid residues differentially contribute to CX3CR1 binding, signaling, and cell adhesion. J. Biol. Chem. 276:21632-21641.
30. Campbell, J.J., et al. 1998. 6-C-kine (SLC), a lymphocyte adhesion-triggering chemokine expressed by high endothelium, is an agonist for the MIP-3beta receptor CCR7. J. Cell Biol. 141:1053-1059.
31. Dawber, T.R., and Kannel, W.B. 1966. The Framingham study. An epidemiological approach to coronary heart disease. Circulation. 34:553-555.
32. Kannel, W.B., Feinleib, M., McNamara, P.M., Garrison, R.J., and Castelli, W.P. 1979. An investigation of coronary heart disease in families. The Framingham offspring study. Am. J. Epidemiol. 110:281-290.
33. Kannel, W.B., and Cupples, A. 1988. Epidemiology and risk profile of cardiac failure. Cardiovasc. Drugs Ther. 1(Suppl. 2):387-395.
34. Combadiere, C., et al. 1998. Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J. Biol. Chem. 273:23799-23804.
35. Faure, S., et al. 2000. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science. 287:2274-2277.
36. McDermott, D.H., et al. 2000. Genetic polymorphism in the HIV coreceptor CX3CR1 and risk of HIV disease. Science. 290:2031a. http://www. sciencemag.org/cgi/reprint/290/5499/203 la.pdf.
37. Smith, M.W., et al. 1997. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City, Cohort (SFCC), ALIVE Study. Science. 277:959-965.
38. Winkler, C., et al. 1998. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science. 279:389-393.
39. Combadiere, C., et al. 2003. Decreased atherosclerotic lesion formation in CX3CR1/Apolipoprotein E double-knockout mice. Circ. 107:1009-1016.
40. Haskell, C.A., et al. 2001. Targeted deletion of CX3CR1 reveals a role for fractalkine in cardiac allografr rejection. J. Clin. Invest. 108:679-688. doi:10.1172/JCI200112976.
41. Robinson, L.A., et al. 2000. A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J. Immunol. 165:6067-6072.
42. Soriano, S.G., et al. 2002. Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J. Neuroimmunol. 125:59-65.
43. Tarozzo, G., Campanella, M., Ghiani, M., Bulfone, A., and Beltramo, M. 2002. Expression of fractalkine and its receptor, CX3CR1, in response to ischaemia-reperfusion brain injury in the rar. Eur. J. Neurosci. 15:1663-1668.
44. Feng, L., et al. 1999. Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. Kidney Int. 56:612-620.
45. Jung, S., et al. 2000. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 20:4106-4114.
46. Zimmerman, P.A., et al. 1997. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol. Med. 3:23-36.
47. Boisvert, W.A., Santiago, R., Curtiss, L.K., and Terkeltaub, R.A. 1998. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation ofmacrophages in atherosclerotic lesions of LDL receptor-deficient mice. J. Clin. Invest. 101:353-363.
48. Szalai, C., et al. 2001. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1-2518 G/G genotype in CAD patients. Atherosclerosis. 158:233-239.
49. Valdes, A.M., et al. 2002. Val64Ile polymorphism in the C-C chemokine receptor 2 is associated with reduced coronary artery calcification. Arterioscler. Thromb. Vasc. Biol. 22:1924-1928.
50. Gonzalez, P., et al. 2001. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun. 2:191-195.
51. Yamada, Y., et al. 2002. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N. Engl J. Med. 347:1916-1923.
52. -/- mice reveals a role for fractalkine in atherogenesis. J. Clin. Invest. 111:333-340. doi:10.1172/JCI200315555.